Opioid therapies and cytochrome p450 interactions.
Article Details
- CitationCopy to clipboard
Gudin J
Opioid therapies and cytochrome p450 interactions.
J Pain Symptom Manage. 2012 Dec;44(6 Suppl):S4-14. doi: 10.1016/j.jpainsymman.2012.08.013.
- PubMed ID
- 23218233 [ View in PubMed]
- Abstract
Adverse drug reactions are common and associated with substantial economic and human costs. Particularly among older adult populations, preventable adverse drug reactions are often caused by drug-drug interactions. All analgesics have side effect profiles and many have known drug-drug interactions. Opioids are recognized as a necessary option for managing moderate-to-severe pain, yet many opioid side effects can be enhanced by metabolic interactions within the liver, involving other drugs, diseases, or genetics.
DrugBank Data that Cites this Article
- Drug Enzymes
Drug Enzyme Kind Organism Pharmacological Action Actions Amoxapine Cytochrome P450 2D6 Protein Humans UnknownSubstrateInhibitorDetails Hydromorphone UDP-glucuronosyltransferase 1-3 Protein Humans NoSubstrateDetails Hydromorphone UDP-glucuronosyltransferase 2B7 Protein Humans NoSubstrateDetails - Drug Reactions
Reaction Details - Drug Interactions
Drugs Interaction Integrate drug-drug
interactions in your softwareHydrocodoneMitotane The metabolism of Hydrocodone can be increased when combined with Mitotane. HydrocodoneRifampicin The metabolism of Hydrocodone can be increased when combined with Rifampicin. HydrocodoneEnzalutamide The metabolism of Hydrocodone can be increased when combined with Enzalutamide. HydrocodoneLumacaftor The metabolism of Hydrocodone can be increased when combined with Lumacaftor. HydrocodoneApalutamide The metabolism of Hydrocodone can be increased when combined with Apalutamide.